8-K: Humana Reaffirms 2025 EPS Guidance Ahead of Investor Meetings

Humana Inc. announced it will reaffirm its full-year 2025 diluted EPS guidance of approximately $13.77 and adjusted EPS of $17.00 during upcoming investor meetings.

Summary

• Humana Inc.'s senior management team is scheduled to meet with investors and analysts between September 1, 2025, and September 30, 2025.
• The company intends to reaffirm its guidance for the year ending December 31, 2025 (FY 2025), for diluted earnings per common share (EPS) at approximately $13.77.
• Humana also plans to reaffirm its adjusted earnings per common share (Adjusted EPS) guidance for FY 2025 at approximately $17.00.
• This guidance is consistent with the guidance previously issued in the company's press release dated July 30, 2025.
• The company will not be commenting on 2026 Medicare Advantage (MA) Star Ratings (Bonus Year 2027) until the Centers for Medicare and Medicaid Services (CMS) releases final data in October.
• Adjusted EPS is a non-GAAP financial measure, which management uses to provide a comprehensive perspective on core operating performance, for planning, decision-making, and incentive compensation.

Sentiment

Score: 6

Explanation: The reaffirmation of guidance is generally positive, indicating stability and meeting prior expectations. However, the lack of immediate commentary on MA Star Ratings introduces a slight element of uncertainty, preventing a higher score.

Positives

• Reaffirmation of full-year 2025 diluted EPS guidance at approximately $13.77, indicating stability in the company's financial outlook.
• Reaffirmation of full-year 2025 adjusted EPS guidance at approximately $17.00, consistent with prior expectations.
• The consistency of guidance with previous statements suggests a stable and predictable financial performance for the current fiscal year.

Negatives

• The company's decision to withhold commentary on 2026 Medicare Advantage (MA) Star Ratings until October could introduce a period of uncertainty for investors regarding future performance in a key business segment.

Risks

• Forward-looking statements in this report are subject to risks, uncertainties, and assumptions, including those detailed in the Risk Factors section of the company's general SEC filings.

Future Outlook

Humana reaffirms its full-year 2025 diluted EPS guidance of approximately $13.77 and adjusted EPS of approximately $17.00. The company anticipates providing updates on 2026 Medicare Advantage Star Ratings after the Centers for Medicare and Medicaid Services (CMS) releases final data in October.

Management Comments

• "Management believes that Adjusted EPS, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company's core operating performance over time."
• "Management uses Adjusted EPS as a consistent and uniform indicator of the Company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation."

Industry Context

The reaffirmation of guidance by Humana, a major player in the healthcare and insurance sector, particularly in Medicare Advantage, signals stability in its core business operations. The decision to withhold commentary on 2026 MA Star Ratings until CMS releases final data in October is a common practice, but these ratings are crucial for MA plans as they directly impact bonus payments and enrollment attractiveness, making future updates highly anticipated within the industry.

Stakeholder Impact

• Shareholders/Investors: Provides clarity on the company's financial outlook for FY 2025, reaffirming previous guidance, which can help in investment decisions. The upcoming investor meetings offer an opportunity for direct engagement.
• Customers (Medicare Advantage members): Future MA Star Ratings (Bonus Year 2027) will impact the attractiveness and benefits of Humana's plans, though this filing only notes a delay in commentary.
• Employees: Stable guidance can indicate business stability, potentially impacting employee morale and job security perceptions.

Next Steps

• Senior management meetings with investors and analysts between September 1, 2025, and September 30, 2025.
• Release of final 2026 Medicare Advantage (MA) Star Ratings data by the Centers for Medicare and Medicaid Services (CMS) in October.
• Company commentary on 2026 MA Star Ratings after CMS releases final data in October.

Key Dates

Recommendation

The reaffirmation of guidance suggests stability and consistency with prior expectations, which typically supports a 'hold' recommendation for existing investors. While the outlook is stable, there are no new positive catalysts to warrant an upgrade, and the pending Medicare Advantage Star Ratings release in October introduces a potential future variable that could influence performance, warranting a cautious approach rather than a 'buy' or 'sell' at this juncture.

Keywords

Humana, HUM, EPS guidance, Adjusted EPS, Medicare Advantage, MA Star Ratings, investor meetings, financial outlook, healthcare, insurance